Capricor Therapeutics, Inc. CAPR 深 滬
等待開盤 07-23 09:30:00 美东时间
18.91
-0.880
-4.45%
華盛通- 最 高19.9204
- 今 開19.72
- 成交量 154.49万股
- 最 低 18.765
- 昨 收 19.79
- 總市值 10.95亿
- 52周最高 40.37
- 市盈率 靜 --
- 換手率 2.67%
- 52周最低 4.30
- 委 比 66.33%
- 總股本 5791.19万
- 歷史最高 171.50
- 量 比 0.94
- 振 幅 5.84%
- 歷史最低 0.88
- 每 手 1
- 風險率 10.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多9 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away fro...
07-10 01:35
期权扫描 | 博通多张Call单暴涨逾300%！期权成交放量逾2.6倍；SpaceX获长线资金卖Put大单抄底
苹果订单点燃股价！博通多张Call单暴涨逾300%；英伟达期权成交冲上500万张，Call单占比逾7成；SpaceX获长线资金卖Put大单抄底>>
07-09 18:01
Four stock-moving events to watch as FDA revives AdComs
The Advisory Committee meetings, a key regulatory step in U.S. drug and MedTech approvals, are making a comeback as the Food and Drug Administration seeks to revisit several controversial decisions ma...
07-02 01:51
Capricor Faces FDA Advisory Review for DMD Therapy
Capricor Therapeutics ( ($CAPR) ) has provided an update. On June 26, 2026, Cap...
06-27 05:53
What's Going On With Capricor Therapeutics Stock On Friday?
Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading lower on Friday, down by 13%. The Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) of the U.S. Food and Drug Administration (FDA) is planning to convene an advisory committee meeting to discuss the company’s Biologics License ...
06-27 02:06
戴尔、闪迪跻身周五市值变动显著个股行列
周五美股多只个股出现大幅波动，覆盖从超大盘到小盘不同市值区间，呈现分化行情。 各市值区间异动个股及相关信息如下： 超大盘股（市值2000亿美元及以上）：迈威科...
06-26 22:41
Capricor Therapeutics To Present Data From Its Current HOPE-2 Open-Label Extension Trial Of Deramiocel For Duchenne Muscular Dystrophy At Parent Project Muscular Dystrophy 2026 Annual Conference
Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company’s lead cell therapy candidate for ...
06-26 21:06
Regenxbio, Replimune among gainers after FDA U-turn on UniQure
Biotechs hit by recent setbacks at the hands of the FDA were making a comeback on Wednesday after the FDA reversed its course on UniQure’s (QURE) gene therapy candidate AMT-130, paving the way for a p...
06-18 02:35
Capricor Therapeutics to Present at Upcoming Investor Conferences
Capricor Therapeutics announced that its senior management will participate in two upcoming investor conferences: the Goldman Sachs 47th Annual Global Healthcare Conference and the Oppenheimer CNS and Neuro-Muscular Summit, both on June 10 in Miami, FL. The company, which focuses on cell and exosome-based therapies for rare diseases, will host fireside chats, investor meetings, and a webcast for the Goldman Sachs event.
06-08 13:25
